Forum Affimed geopend

2.102 Posts, Pagina: « 1 2 3 4 5 6 ... 31 32 33 34 35 36 37 38 39 40 41 ... 102 103 104 105 106 » | Laatste
De Troon Jan
0
Alles zakte afgelopen donderdag en vrijdag...... dat is de trent, en daar doe je niets tegen.....
wijzerplaat
0
Published on LinkedIn: 19 minutes ago

#MultipleMyeloma is the third most common hematologic #cancer; and many patients can eventually relapse or become resistant to current therapies. Utilizing our technology, we’re exploring innate immune approaches to help patients with this disease.

bit.ly/3dzT4Dq
Wil Helmus
0
quote:

Will73 schreef op 29 juli 2020 19:40:


Wat is er aan de hand ???? We blijven maar zakken????

Biotech in het algemeen gaat niet zo lekker deze week. Kijk maar eens naar de XBI index. De afgelopen 5 dagen in een downtrend. Hopen dat we snel weer in een uptrend komen, want het gaat best hard nu
Will73
0
Dit is idd best schrikken, was vol positieve verwachtingen toch weer ingestapt. Hoop op herstel idd.
Dank je Wilhelmus
RW1963
0
quote:

Will73 schreef op 29 juli 2020 19:40:


Wat is er aan de hand ???? We blijven maar zakken????


Ik zie het portefeuille breed. Niet leuk om te zien. Hoop gauw op betere tijden, vooral bij Galapagos (de grootste in mijn portefeuille)
StofkeVN
0
Introducing Affimed (NASDAQ:AFMD), A Stock That Climbed 76% In The Last Three Years

Affimed N.V. (NASDAQ:AFMD) shareholders might be concerned after seeing the share price drop 22% in the last month. But that doesn't change the fact that the returns over the last three years have been pleasing. To wit, the share price did better than an index fund, climbing 76% during that period

Gaven that Affimed didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Affimed's revenue trended up 74% each year over three years. That's well above most pre-profit companies. The share price rise of 21% per year throughout that time is nice to see, and given the revenue growth, that gain seems somewhat justified. So now might be the perfect time to put Affimed on your radar. If the company is trending towards profitability then it could be very interesting.

A Different Perspective

It's nice to see that Affimed shareholders have received a total shareholder return of 25% over the last year. Notably the five-year annualised TSR loss of 11% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important.
Wil Helmus
0
Morgen aandeelhoudersvergadering. Punt 11 (uit mijn hoofd) van de agenda is het laten vallen van de overnamebescherming. Indien de aandeelhouders hiermee akkoord gaan kan er weleens meer fantasie in de koers komen
StofkeVN
0
Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020
Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2020 results on Tuesday, August 11, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and corporate developments.

The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 8855368 approximately 15 minutes prior to the call.

To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.
Wil Helmus
0
Geen overnamebescherming dus:

It is proposed to abolish the cumulative preference shares which were included in the articles of association of the Company to allow the Company to set-up an anti-takeover mechanism. The Company has decided to not implement such mechanism at this time and it is therefore no longer a need to keep the cumulative preference shares.
Hulskof
0
Zouden we dat negatief kunnen uitleggen? Zo van, we hebben bij nader inzien toch geen echte baanbrekende technologie die onbetaalbaar zal blijken, dus laat ons maar overnemen?
Wil Helmus
0
quote:

Hulskof schreef op 5 augustus 2020 09:48:


Zouden we dat negatief kunnen uitleggen? Zo van, we hebben bij nader inzien toch geen echte baanbrekende technologie die onbetaalbaar zal blijken, dus laat ons maar overnemen?

Dat lijkt mij wat vergezocht. Ik sluit niet uit dat achter de schermen alles in het werk wordt gezet voor een eventuele overname door Roche/Genentec. Misschien als er wat meer resultaten bekend zijn en het er allemaal goed uit blijft zien? Ik ben trouwens wel bekend naar de mening van Tom3 hieromtrent
Wil Helmus
0
Tweet van 10 juli van Affimed kenner Dieter Hovekamp:

$AFMD nice to see 10% repurchase plan in own shares again, no takeover prevention anymore and new appointments to the BoD -- all ready for the big buyout?

Ik zeg niet dat het ervan gaat komen en gok daar ook zeker niet op, maar hoop wel dat er nu wat overnamefantasie in de koers gaat komen. We weten allemaal wat dat deed met de koers van Arrowhead....
StofkeVN
1
Affimed Announces Two New Appointments to Its Supervisory Board
Heidelberg, Germany, August 5, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointments of Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory Board. Both these appointments were approved during the Annual General Meeting of Shareholders which took place on August 4, 2020.

“Affimed is pleased to welcome Annalisa and Harry, both highly experienced professionals in their respective fields, to the Supervisory Board” said Dr. Thomas Hecht, Chairman of Affimed’s Supervisory Board. “Annalisa is a visionary leader who knows how to translate science from bench to bedside. Harry is an accomplished financial executive who is well suited to help drive value-creating strategies for the company. Together, these new appointments position us to ensure sound corporate governance by further strengthening our biotech industry know-how and experience as well as our diversity.”

Dr. Jenkins, with more than 25 years of global pharmaceutical experience, brings a wealth of expertise in advancing clinical programs through development and to regulatory approval. Dr. Jenkins serves on the Board of Directors for a number of publicly and privately held biotechnology and life science companies. In addition, she is a committee member of the science board to the U.S. Food and Drug Administration (FDA), which advises FDA leadership on complex scientific and technical issues. Dr. Jenkins served as the Chief Executive Officer of PlaqueTec Ltd. and Dimension Therapeutics. Prior leadership roles held by Dr. Jenkins include Executive Vice President, Global Research and Development­ at Merck Serono Pharmaceuticals as well as several leadership positions at Bristol-Myers Squibb. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital at the University of London and subsequently trained in cardiovascular medicine in the UK National Health Service.

Mr. Welten brings significant financial and U.S. market expertise to Affimed. He is chairman and member of the board of directors of several biotechnology companies in Switzerland, Germany and the U.S. Over the last 20 years, Mr. Welten served as Chief Financial Officer of both public as well as venture capital financed biotech companies. Mr. Welten has served in senior roles at UBS in Switzerland and New York for the first 15 years of his career. Mr. Welten has degrees in Banking, Finance and Economics as well as an MBA from Columbia University, NY, USA.
2.102 Posts, Pagina: « 1 2 3 4 5 6 ... 31 32 33 34 35 36 37 38 39 40 41 ... 102 103 104 105 106 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 7 mei 2021 22:00
Koers 9,810
Verschil +0,110 (+1,13%)
Hoog 10,110
Laag 9,697
Volume 1.720.499
Volume gemiddeld 3.540.352
Volume gisteren 1.016.414